These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 1386555)

  • 1. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
    Kikuchi T; Watanabe M; Ohno T
    Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
    Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
    Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
    Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
    Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
    Nakamura H; Ishiguro K; Mori T
    Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing effect of pokeweed mitogen on the proliferation and the cytotoxicity of lymphokine-activated killer cells.
    Kimoto Y; Tanaka T; Fujiwara A; Fujita M; Taguchi T
    Jpn J Cancer Res; 1992 Jun; 83(6):631-7. PubMed ID: 1379578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
    Anderson PM; Bach FH; Ochoa AC
    Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients.
    Karimine N; Nanbara S; Arinaga S; Asoh T; Ueo H; Akiyoshi T
    J Surg Oncol; 1994 Mar; 55(3):179-85. PubMed ID: 8176929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
    Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
    Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.
    Ferrarini M; Ferrero E; Fortis C; Poggi A; Zocchi MR
    Br J Cancer; 1990 Nov; 62(5):754-7. PubMed ID: 1700922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.
    Grimm EA; Bruner JM; Carinhas J; Köppen JA; Loudon WG; Owen-Schaub L; Steck PA; Moser RP
    Cancer Immunol Immunother; 1991; 32(6):391-9. PubMed ID: 1848799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
    Koyama S
    J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.